Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp.

Critical Care Medicine

Volumn 36, Issue 7, 2008, Pages 2034-2039

  Playford, E Geoffrey ^a,b   Marriott, Deborah ^c,d   Nguyen, Quoc ^d   Chen, Sharon ^e   Ellis, David ^f,g   Slavin, Monica ^h   Sorrell, Tania C ^e,i  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Discipline of Psychiatry   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^g UNIVERSITY OF ADELAIDE   (Australia)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Candida; Candidemia; Candidiasis; Fungemia; Intensive care unit; Risk factors

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGED; ANTIFUNGAL RESISTANCE; BLOODSTREAM INFECTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CLINICAL FEATURE; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DRUG EXPOSURE; FEMALE; FUNGUS IDENTIFICATION; GASTROINTESTINAL SURGERY; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; ARTICLE; AUSTRALIA; BLOOD; CANDIDIASIS; CROSS INFECTION; INCIDENCE; MICROBIOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RISK FACTOR; STATISTICS;

ANTIFUNGAL AGENTS; AUSTRALIA; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 47249139580     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181760f42     Document Type: Article

References (25)

1. Eggimann P, Garbino J, Pittet D: Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3:685-702
2. Ostrosky-Zeichner L, Pappas P: Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34:857-863
3. Blot SI, Vandewoude KH, Hoste EA, et al: Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113:480-485
4. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163
5. Trick WE, Fridkin SK, Edwards JR, et al: Secular trend of hospital-acquired Candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-630
6. Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-3645
7. Garey KW, Rege M, Pai MP, et al: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006; 43:25-31
8. Chen S, Slavin M, Nguyen Q, et al: Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12:1508-1516
9. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al: Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23:23-30
10. Leleu G, Aegerter P, Guidet B: Systemic candidiasis in intensive care units: A multicenter, matched-cohort study. J Crit Care 2002; 17:168-175
11. Tortorano AM, Caspani L, Rigoni AL, et al: Candidosis in the intensive care unit: A 20-year survey. J Hosp Infect 2004; 57:8-13
12. Rangel-Frausto MS, Wiblin T, Blumberg HM, et al: National epidemiology of mycoses survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29:253-258
13. Shorr AF, Lazarus DR, Sherner JH, et al: Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007; 35:1077-1083
14. Pappas PG, Rex JH, Sobel JD, et al: Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-189
15. Abi-Said D, Anaissie E, Uzun O, et al: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-1128
16. Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20: 115-125
17. Viscoli C, Girmenia C, Marinus A, et al: Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-1079
18. Takakura S, Fujihara N, Saito T, et al: Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 2004; 23:380-388
19. Lin MY, Carmeli Y, Zumsteg J, et al: Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: A case-case-control study. Antimicrob Agents Chemother 2005; 49: 4555-4560
20. Hajjeh RA, Sofair AN, Harrison LH, et al: Incidence of bloodstream infections due to Candida species and in vitro susceptibili- ties of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-1527
21. Nguyen MH, Peacock JE Jr, Tanner DC, et al: Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155:2429-2435
22. Kunova A, Trupl J, Dluholucky S, et al: Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. Clin Infect Dis 1995; 21:226-227
23. Blot S, Vandewoude K, Hoste E, et al: Outcome in critically ill patients with candidal fungaemia: Candida albicans vs Candida glabrata. J Hosp Infect 2001; 47:308-313
24. Davis SL, Vazquez JA, McKinnon PS: Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candi-demia in nonneutropenic patients. Ann Pharmacother 2007; 41:568-573
25. Malani A, Hmoud J, Chiu L, et al: Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005; 41: 975-981